|
A Critical Review: Blood and Clinical Hematology Disorders in Covid-19
|
|
| Author:
|
MUHAMMAD DARWIN PRENGGONO, MOHAMMAD RUDIANSYAH, NUVITA HASRIANTI
|
| Abstract:
|
Severe acute respiratory coronavirus 2 (SARS–CoV– 2) is a pathogen virus from the infectious Coronavirus
disease which was reported first in Wuhan, Hubei Province, by the People’s Republic of China to WHO on
December 31st, 2019. Due to its rapid and global spread that infected about 2 million people with mortality
rate of more than 150.000, it was declared a pandemic on March 12th, 2020. The opening speech of the WHO
Director General on the media about COVID-19 was carried out on March 18th, 2020, and it was stated that
the virus needs rapid and large scale tests. Therefore, Solidarity Test was chosen because it may help reduce
80% of the time that is needed in a research rather than random clinical check that requires longer time. Based
on the data from several countries, it was found that COVID-19 is a systemic infection disease that brings
significant effect to hematopoietic systems and hemostasis such as low ALC and high LDH which was found in
many ICU patients. Lymphopenia is considered to be a cardinal laboratory finding with potentials of being a
prognosis. Blood disorders in COVID-19 are divided are divided into two, namely malignant and nonmalignant. However, this study mainly focused on non-malignant blood disorders.
|
| Keyword:
|
COVID-19, blood disorders, coagulopathy, laboratory, therapy
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.079
|
| Download:
|
Request For Article
|
|
|